KRAS and familial pancreatic carcinoma: Additionally, P6@siKRAS, a dual-functional nanoparticle combining a pyrrole radical cation (P6•+) with KRAS siRNA, simultaneously degrades mutp53 and suppresses oncogenic KRAS, demonstrating potent therapeutic efficacy in pancreatic cancer [134].